voxelotor 500 MG Oral Tablet [Oxbryta]
- RxCUI
- 2265689
- RxNorm name
- voxelotor 500 MG Oral Tablet [Oxbryta]
- Display name
- voxelotor 500 MG Oral Tablet [Oxbryta]
- Full name
- voxelotor 500 MG Oral Tablet [Oxbryta]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:54
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OXBRYTA | VOXELOTOR | Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. | 3c557fac-29ec-483f-b691-8a935d4decc3 | 2023-12-26 | Warnings, Adverse reactions | 2265689 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 3c557fac-29ec-483f-b691-8a935d4decc3 | OXBRYTA 500 MG Oral Tablet [PSN] · voxelotor 500 MG Oral Tablet [Oxbryta] [SBD] · Oxbryta 500 MG Oral Tablet [SY] | 3 | 13 | These highlights do not include all the information needed to use OXBRYTA safely and effectively. See full prescribing information for OXBRYTA. OXBRYTA ® (voxelotor) tablets, for oral use OXBRYTA ® (voxelotor) tablets for oral suspension Initial U.S. Approval: 2019 | 20231226 |